https://www.selleckchem.com/products/icrt14.html CNR was highest at 20 s in 58% of lesions but was highest at 10 or 25 s in 42%. Overall, there was no significant difference in mean CNR between the three arterial acquisitions. CONCLUSION A wide detector axial liver CT protocol with three acquisitions in the hepatic arterial phase is technologically feasible and results in diagnostic image quality. With this protocol, peak subjective and objective hyperenhancing lesion conspicuity may be earlier or later than 20 s in up to 40% of lesions.OBJECTIVES To evaluate and compare the diagnostic potential of whole-body MRI and whole-body 18F-FDG PET/MRI for N and M staging in newly diagnosed, histopathologically proven breast cancer. MATERIAL AND METHODS A total of 104 patients (age 53.4 ± 12.5) with newly diagnosed, histopathologically proven breast cancer were enrolled in this study prospectively. All patients underwent a whole-body 18F-FDG PET/MRI. MRI and 18F-FDG PET/MRI datasets were evaluated separately regarding lesion count, lesion localization, and lesion characterization (malignant/benign) as well as the diagnostic confidence (5-point ordinal scale, 1-5). The N and M stages were assessed according to the eighth edition of the American Joint Committee on Cancer staging manual in MRI datasets alone and in 18F-FDG PET/MRI datasets, respectively. In the majority of lesions histopathology served as the reference standard. The remaining lesions were followed-up by imaging and clinical examination. Separately for nodal-positive and nodal-negative wsion-based analysis, 18F-FDG PET/MRI showed a significantly better performance in correctly determining malignant lesions (85.8% vs. 67.1%, difference 18.7% (95% CI 0.13-0.26), p  less then  0.0001) and offered a superior diagnostic confidence compared with MRI alone (4.1 ± 0.7 vs. 3.4 ± 0.7, p  less then  0.0001). CONCLUSION 18F-FDG PET/MRI has a better diagnostic accuracy for N staging in primary breast cancer patients and prov